We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wedbush analyst David Nierengarten maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...

Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Stock analysts at Wedbush lowered their Q1 2025 earnings estimates for Blueprint Medicines in a research report issued on Wednesday ...

In the current U.S. market landscape, significant volatility has been observed as major indices like the Dow Jones and Nasdaq Composite experience sharp declines due to ongoing tariff concerns and ...

Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $121.90. The stock’s 50 day moving average is $88.95 and its 200-day moving average is $93.26.

Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects ...

Learn more about whether Alvotech or Blueprint Medicines Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report) ...

On Thursday, 27 March 2025, Blueprint Medicines (NASDAQ: BPMC) presented at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company outlined its growth ...

Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...